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Abstract
Background: To explore the association between serum uric acid (SUA) levels, metabolic syndrome (MetS) and
cardiovascular disease (CVD) in patients treated with lipid-lowering agents from multiple centers in China.
Method: We investigated 15,478 participants who had been documented with recorded SUA in the DYSlipidemia
International Study which included 25,697 patients, aged 45 years old or older, who were treated with lipid-lowering
agents from 122 centers between April 2012 and October 2012. Logistic regression analysis was performed to examine
the association between SUA levels, MetS and CVD.
Result: After adjusting for multi-variables, hyperuricemia (the highest category of SUA level) showed a significantly
higher risk of MetS compared to the lowest category[according to NCEP-ATPIII criteria, odds ratio (OR) 1.51, 95 %
confidence interval (CI) (1.30,1.74) in men, OR 2.35 95 % CI (2.00,2.75) in women; and according to IDF criteria, OR
1.40 95 % CI (1.20,1.63) in men, OR 1.65 95 % CI (1.41,1.94) in women]. In addition, elevated SUA concentration
was shown to be associated with coronary heart disease (CHD) (OR 1.26 95 % CI (1.09, 1.45) in men, and OR 1.27,
95 % CI (1.07, 1.50) in women) and heart failure (HF) (OR 1.61 95 % CI (1.15, 2.24) in men, and OR 1.91, 95 % CI
(1.29, 2.82) in women).
Conclusion: Our research suggested a positive association between SUA levels and MetS in Chinese patients
receiving lipid-lowering therapy. Elevated SU levels were positively associated independently of measured
confounders to CHD and HF.
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Background
Uric acid is a final enzymatic product from purine deg-
radation in humans. During the past several decades, the
prevalence of hyperuricemia appears to be increasing
both in western countries and China [1, 2]. There is a
growing body of evidence to show that hyperuricemia or
elevated serum uric acid (SUA) levels, even within the
normal range, are associated with metabolic syndrome
(MetS) and its components [3–7]. This relationship is
found in children, adolescents and elderly people [8, 9].
Furthermore, whether patients with elevated SUA con-
centration suffer a higher risk of cardiovascular disease
(CVD) is still not conclusive [10–14].
MetS as a CVD risk factor includes the clustering of
abdominal obesity, insulin resistance, dyslipidemia, and
elevated blood pressure. Insulin resistance is considered
to be one of the two central features of patients with
MetS [15]. It has been widely demonstrated that MetS is
associated with 2-to 3-fold increase in CVD risk and
nearly 7-fold for incidence of type 2 diabetes mellitus,
(DM) and it also contributes to CVD related mortality
and all-cause mortality [16–18].
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There are several studies which have reported that there
was a positive association between SUA levels and MetS
and its components, and also that it was adversely related
with elevating CVD risk in Chinese populations. However,
few of these studies have explored the direct association
between SUA levels and CVD especially in the mainland
of China [4, 6, 7, 9, 19]. In addition, the data from subjects
from multiple centers in China are still limited. The aim
of this present study was to investigate the association be-
tween increasing SUA levels, MetS and CVD in partici-
pants aged 45 years old or older by using the data from
the DYSlipidemia International Study (DYSIS).
Methods
Participants and investigators
DYSIS is a series of epidemiologic cross-sectional studies
which are performed mainly to assess the blood lipid
goal attainment rates in patients receiving lipid-lowering
therapy all over the world. 25,697 outpatients from 122
centers in six representative regions across China were
included for DYSIS-China between April 2012 and Oc-
tober 2012 [20]. All of the outpatients suffered from dys-
lipidemia, and received a lipid-lowering therapy for at
least 3 months. A total number of 15,478 participants
were documented for their SUA level during their visit
and were considered for this studied. After excluding 77
subjects who had no data for waist circumference (WC),
height or blood pressure, 15,401 participants were eli-
gible for inclusion in our study. All of the participants
were aged from 45 to 98 years old. The investigators in
our present study were internists, cardiologists, endocri-
nologists, geriatricians, and neurologists. All the partici-
pants provided informed consent to participant in the
study. Our study was approved by the Ethics Committee
of Peking University People’s Hospital. The approval
documents for ethics were regarded as the center of
ethical documents for the present study. In addition,
informed consent have been provided by all of the par-
ticipants included in the present study.
Data collection
Data on socio-demographics (gender, age, and national-
ity), cardiovascular risk profile (first grade family history
of premature CVD, sedentary lifestyle, alcohol consump-
tion, and smoking), cardiovascular history [coronary
heart disease(CHD), peripheral arterial disease (PAD),
and symptomatic chronic heart failure New York Heart
Association(NYHA) class II-IV], and the drugs used for
lipid-lowering, DM, hypertension, and antiplatelet were
recorded by clinicians at one visit.
Anthropometric data were collected by the clinicians
as well. Weight (to the nearest 0.5 Kg) and height (to
the nearest 0.5 cm) were measured with light clothes
and without shoes. Both systolic and diastolic blood
pressures (SBP/DBP) were measured after the participants
had rested in the seated position for at least 5 min. WC,
also to the nearest 0.5 cm, was measured in the standing
position, and the measurement point was the midpoint be-
tween the superior border of the iliac crest and the inferior
costal margin. Biochemical markers such as triglyceride
(TG), total cholesterol (TC), high density lipoprotein chol-
esterol (HDL-C), low density lipoprotein cholesterol (LDL-
C), fasting plasma, glucose (FPG) (documented in 9864
subjects), and SUA were documented at one visit.
Definition of MetS and CVD
The diagnosis of MetS was attained by using both the def-
inition of the National Cholesterol Education Program
Adult Treatment Panel III (NCEP ATP III) [21], and the
criteria recommended by the International Diabetes Fed-
eration (IDF) [22].According to the NCEP ATP III criteria,
participants were considered to have MetS if they had at
least three of these five following items: 1) abdominal
obesity: WC >102 cm in men and >88 cm in women; 2)
TG ≥ 1.70 mmol/L(150 mg/dl); 3) HDL-C <40 mg/dl
(1.04 mmol/L) in men and HDL-C <50 mg/dl
(1.30 mmol/L) in women; 4) blood pressure: SBP ≥
130 mmHg, or DBP ≥ 85 mmHg, or previously diagnosed
hypertension; 5) fasting plasma glucose: ≥ 5.6 mmol/L
(100 mg/ dl), or previously diagnosed DM. While accord-
ing to the IDF criteria, participants with central obesity
(WC > 90 cm in men and >80 cm in women) plus any two
of the following criteria were defined as having the MetS:
1) raised triglycerides: ≥ 1.7 mmol/l (150 mg/dl) or
specific treatment for this lipid abnormality; 2) reduced
HDL-cholesterol: < 1.03 mmol/l (40 mg/dl) in males
and < 1.29 mmol/l (50 mg/dl) in females or specific treat-
ment for this lipid abnormality; 3) raised blood pressure:
systolic ≥ 130 mmHg or diastolic ≥ 85 mmHg or treatment
of previously diagnosed hypertension; 4) raised fasting
plasma glucose: fasting plasma glucose ≥ 5.6 mmol/l
(100 mg/dl) or previously diagnosed type 2 diabetes
(T2DM).
Central obesity was defined as a WC >90 cm in men
and >80 cm in women. Hypertension was defined as
previously diagnosed hypertension, or patients treated
with hypotensors. Hyperuricemia was defined as SUA
>420 umol/l in men and >360 umol/l in women. CHD
was confirmed as suffering a myocardial infarction or
angina, or received a percutaneouse coronary interangio-
plasty, or coronary artery bypass grafting surgery. Heart
failure (HF) was confirmed as NYHA class II-IV. PAD
was confirmed as receiving peripheral artery reconstruc-
tion surgery.
Categories and statistical analysis
All statistical analyses were carried out using the SAS
9.2 (SAS Institute Inc., Cary, NC, USA). We classified
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participants on the basis of sex-specific quartiles of SUA
in the normal range and hyperuricemia. The five categor-
ies are <280 umol/l, 280–320 umol/l, 320–370 umol/l,
370–420 umol/l, >420 umol/l for males, and <230 umol/l,
230–270 umol/l, 270–310 umol/l, 310–360 umol/l, >360
umol/l for females, respectively. Continuous variables
with a normal distribution were presented by mean ±
standard deviation. Meanwhile, categorical variables
were described by frequency and percentage. Analysis
of variance (ANOVA) was performed to access the con-
tinuous variables. Chi-square test was then used to cal-
culate the differences between categorical variables. A
logistic regression analysis was performed to examine
the association between MetS, CVD and the SUA cat-
egories of 280–320 umol/l or greater compared to the
lowest SUA category of <280 umol/l for men, and the
SUA categories of 230–270 umol/l or greater compared
to the lowest SUA category of <230 umol/l for women,
respectively. Unadjusted odds ratios (OR) and multiple
adjusted OR were both calculated. Furthermore, a step-
wise multiple linear regression analysis was used to
evaluate the association between metabolic risk factors
and SUA concentration sex-specifically. At last, we de-
scribe the prevalence of MetS according to the sex-
specific SUA categories. Statistical significance was set
at a probability level of less than 0.05.
Table 1 Baseline clinical features of the participants according to serum uric acid level in men
SUA levels (μmol/L) P value
<280 280 ~ 320 320 ~ 370 370 ~ 420 >420
(n = 1748) (n = 1376) (n = 1886) (n = 1452) (n = 1788)
Q1 Q2 Q3 Q4 Q5
Age(years) 66.4(11.09) 65.6(10.80) 65.8(11.19) 65.8(11.17) 66.2(11.48) 0.221
Age≥ 65 (%) 955(54.6 %) 735(53.4 %) 1004(53.2 %) 774(53.3 %) 964(53.9 %) 0.918
Current smoker (%) 405(23.2 %) 305(22.2 %) 436(23.1 %) 307(21.1 %) 386(21.6 %) 0.015
Alcohol consumption (%) 304(17.4 %) 229(16.6 %) 302(16.0 %) 252(17.4 %) 310(17.3 %) 0.485
Sedentary lifestyle (%) 392(22.4 %) 293(21.3 %) 427(22.6 %) 358(24.7 %) 436(24.4 %) 0.145
Family history of premature CVD (%) 151(8.6 %) 114(8.3 %) 153(8.1 %) 133(9.2 %) 179(10.0 %) 0.282
Height (cm) 169.6(5.73) 170.0(5.54) 170.2(5.78) 169.9(5.52) 169.8(5.83) 0.009
Weight (kg) 70.23(10.30) 70.91(10.06) 71.78(10.10) 72.07(9.94) 72.96(10.85) <0.001
BMI (kg/m2) 24.39(3.11) 24.50(3.00) 24.74(3.04) 24.93(2.96) 25.28(3.33) <0.001
WC (cm) 88.65(11.08) 89.16(10.63) 89.75(11.36) 90.44(10.57) 91.09(11.15) <0.001
SBP (mmHg) 130.3(15.25) 129.3(15.41) 130.2(14.67) 130.8(16.16) 131.4(15.71) 0.004
DBP (mmHg) 77.5(9.68) 77.6(9.47) 78.1(9.67) 78.1(9.99) 78.4(10.18) 0.049
FPG (mmol/L)a 6.82(2.88) 6.34 (2.27) 6.29(2.28) 6.34(2.35) 6.22(2.11) <0.001
TC (mmol/L) 4.25(1.13) 4.23 (1.14) 4.22(1.12) 4.27(1.14) 4.28(1.14) 0.577
LDL-C (mmol/L) 2.44 (0.88) 2.43 (0.91) 2.44 (0.94) 2.43 (0.91) 2.42(0.91) 0.924
HDL-C (mmol/L) 1.23(0.35) 1.22 (0.35) 1.17 (0.31) 1.17(0.30) 1.12(0.31) <0.001
TG (mmol/L) 1.52 (1.21) 1.65(1.32) 1.71 (1.36) 1.87(1.50) 2.18 (1.88) <0.001
NonHDL-C (mmol/L) 3.01 (1.08) 3.01 (1.09) 3.05(1.07) 3.10(1.09) 3.16(1.08) 0.001
Diabetes mellitus (%) 819(46.9 %) 529(38.4 %) 679(36.0 %) 501(34.5 %) 592(33.1 %) <0.001
Hypertension (%) 1100(62.9 %) 867(63.0 %) 1286(68.2 %) 1025(70.6 %) 1319(73.8 %) <0.001
CHD (%) 705(40.3 %) 594(43.2 %) 826(43.8 %) 663(45.7 %) 849(47.5 %) <0.001
Cerebrovascular disease (%) 384(22.0 %) 256(18.6 %) 379(20.1 %) 284(19.6 %) 335(18.7 %) 0.099
HF (%) 63(3.6 %) 44(3.2 %) 87(4.6 %) 60(4.1 %) 107(6.0 %) 0.001
Peripheral arterial disease (%) 31(1.8 %) 17(1.2 %) 20(1.1 %) 24(1.7 %) 25(1.4 %) 0.378
Antihypertention agents (%) 1012(57.9 %) 827(60.1 %) 1209(64.1 %) 960(66.1 %) 1255(70.2 %) <0.001
Diuretic agents (%) 52(3.0 %) 33(2.4 %) 77(4.1 %) 76(5.2 %) 139(7.8 %) <0.001
Antiplatelet agents (%) 1241(71.0 %) 981(71.3 %) 1370(72.6 %) 1057(72.8 %) 1293(72.3 %) 0.710
aAmong 8250 men, 5211 subjects were documented the FBG. (1107 for Q1, 873 for Q2, 1205 for Q3, 907 for Q4, 1119 for Q5)
Abbreviations: SUA serum uric acid, CVD cardiovascular disease, WC waist circumference, CHD coronary artery disease, SBP systolic blood pressure, DBP diastolic
blood pressure, TG triglyceride, TC total cholesterol, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol, FPG fasting plasma
glucose, HF heart failure, BMI body mass index
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Results
Clinical characteristics according to serum uric acid levels
The clinical characteristics of the 15,401 eligible partici-
pants are summarized according to sex-specific categor-
ies of the SUA levels. (Table 1 and Table 2). Participants
were older in the highest category of SUA level (hyper-
uricemia) in women but not in men. Higher SUA levels
were significantly adversely associated with weight, body
mass index (BMI), WC, SBP, TG, and nonHDL-C, but
inversely associated with HDL-C and FPG in both gen-
ders (all p values for trend <0.05). Subjects with the
highest SUA category exhibited a higher prevalence of
hypertension, central obesity, CHD, HF and diuretic
agents in both men and women (all p values for trend
<0.001). In addition, there existed a higher prevalence of
PAD in women with the highest SUA category but not
in men. However, there was no significant association
between SUA levels and alcohol consumption, family
history of premature CVD, TC, LDL-C, and cerebrovas-
cular disease.
The association between serum uric acid categories and
MetS
As presented in Table 3 and Table 4, compared with the
lowest category of SUA level, the highest category was
presented a higher OR for MetS in both genders. Even
after multiple adjustments for age, smoking, alcohol con-
sumption, sedentary lifestyle, family history of premature
Table 2 Baseline clinical features of the participants according to serum uric acid level in women
SUA levels (μmol/L) P value
<230 230 ~ 270 270 ~ 310 310 ~ 360 >360
(n = 1359) (n = 1325) (n = 1436) (n = 1389) (n = 1642)
Age(years) 64.9(10.05) 65.1(9.70) 65.5(9.67) 66.2(9.76) 68.5(9.91) <0.001
Age≥ 65 (%) 680(50.0 %) 673(50.8 %) 755(52.6 %) 766(55.1 %) 1058(64.4 %) <0.001
Current smoker (%) 20(1.5 %) 22(1.7 %) 35(2.4 %) 29(2.1 %) 19(1.2 %) 0.142
Alcohol consumption (%) 7(0.5 %) 7(0.5 %) 13(0.9 %) 7(0.5 %) 9(0.5 %) 0.602
Sedentary lifestyle (%) 228(16.8 %) 233(17.6 %) 257(17.9 %) 279(20.1 %) 336(20.5 %) 0.039
Family history of premature CVD (%) 108(7.9 %) 112(8.5 %) 135(9.4 %) 137(9.9 %) 176(10.7 %) 0.075
Height (cm) 158.1(5.43) 158.3(5.34) 158.3(5.30) 158.1(5.37) 157.7(5.62) 0.045
Weight (kg) 59.92(9.58) 60.64(9.19) 61.36(9.12) 61.85(9.78) 62.52(10.06) <0.001
BMI (kg/m2) 23.92(3.34) 24.19(3.31) 24.46(3.20) 24.72(3.53) 25.09(3.58) <0.001
WC (cm) 83.34(10.21) 83.69(10.15) 84.36(10.18) 84.62(10.79) 86.38(11.34) <0.001
SBP (mmHg) 130.1(16.57) 130.0(15.63) 130.2(16.11) 130.5(16.27) 132.2(16.53) <0.001
DBP (mmHg) 77.1(9.42) 77.4(9.43) 77.0(9.61) 77.1(10.03) 77.1(9.88) 0.889
FPG (mmol/L)a 6.62(2.88) 6.35(2.42) 6.21 (2.05) 6.35 (2.25) 6.32 (2.22) 0.007
TC (mmol/L) 4.80 (1.14) 4.83(1.21) 4.85(1.23) 4.78(1.18) 4.79(1.20) 0.504
LDL-C (mmol/L) 2.75 (0.96) 2.76(0.97) 2.76(1.02) 2.76(1.02) 2.76(1.04) 0.964
HDL-C (mmol/L) 1.45(0.39) 1.40(0.37) 1.36 (0.35) 1.32(0.36) 1.26(0.34) <0.001
TG (mmol/L) 1.63 (1.22) 1.73 (1.08) 1.89 (1.48) 1.98 (1.39) 2.20 (1.55) <0.001
NonHDL-C (mmol/L) 3.36(1.10) 3.43(1.16) 3.48 (1.20) 3.46(1.13) 3.53 (1.16) 0.001
Diabetes mellitus (%) 509(37.5 %) 443(33.4 %) 485(33.8 %) 521(37.5 %) 669(40.7 %) <0.001
Hypertension (%) 802(59.0 %) 816(61.6 %) 955(66.5 %) 994(71.6 %) 1270(77.3 %) <0.001
CHD (%) 389(28.6 %) 411(31.0 %) 473(32.9 %) 496(35.7 %) 661(40.3 %) <0.001
Cerebrovascular disease (%) 214(15.7 %) 202(15.2 %) 207(14.4 %) 196(14.1 %) 265(16.1 %) 0.493
HF (%) 37(2.7 %) 47(3.5 %) 52(3.6 %) 61(4.4 %) 123(7.5 %) <0.001
Peripheral arterial disease (%) 8(0.6 %) 9(0.7 %) 19(1.3 %) 15(1.1 %) 26(1.6 %) 0.044
Antihypertention agents (%) 740(54.5 %) 757(57.1 %) 902(62.8 %) 937(67.5 %) 1213(73.9 %) <0.001
Diuretic agents (%) 44(3.2 %) 59(4.5 %) 78(5.4 %) 80(5.8 %) 159(9.7 %) <0.001
Antiplatelet agents (%) 769(56.6 %) 765(57.7 %) 861(60.0 %) 868(62.5 %) 1117(68.0 %) <0.001
aAmong 7151 women, 4653 subjects were documented the FBG. (852 for Q1, 843 for Q2, 933 for Q3, 911 for Q4, 1114 for Q5)
Abbreviations: SUA serum uric acid, CVD cardiovascular disease, WC waist circumference, CHD coronary artery disease, SBP systolic blood pressure, DBP diastolic
blood pressure, TG triglyceride, TC total cholesterol, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol, FPG fasting plasma
glucose, HF heart failure, BMI body mass index
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Table 3 The association between SUA and MetS, hypertension, central obesity, and CVD in men
SUA levels (μmol/L)
<280 280 ~ 320 320 ~ 370 370 ~ 420 >420
Q1 Q2 Q3 Q4 Q5
MetS ATP
Unadjusted 1(reference) 1.02 (0.88,1.19) 1.16 (1.01,1.34) 1.23 (1.06,1.43) 1.71 (1.49,1.97)
Model 1 1(reference) 1.01 (0.87,1.18) 1.15 (1.00,1.32) 1.22 (1.05,1.42) 1.71 (1.49,1.97)
Model 2 1(reference) 1.01 (0.87,1.18) 1.15 (1.00,1.33) 1.21 (1.04,1.40) 1.71 (1.48,1.96)
Model 3a 1(reference) 1.03 (0.88,1.20) 1.16 (1.01,1.34) 1.22 (1.05,1.42) 1.72 (1.49,1.98)
Model 41 1(reference) 1.02 (0.87,1.20) 1.11 (0.96,1.28) 1.13 (0.96,1.31) 1.51 (1.30,1.74)
MetS IDF
Unadjusted 1(reference) 1.00 (0.86,1.16) 1.20 (1.04,1.37) 1.28 (1.10,1.48) 1.68 (1.46,1.92)
Model 1 1(reference) 0.98 (0.85,1.14) 1.18 (1.03,1.36) 1.26 (1.09,1.46) 1.68 (1.46,1.93)
Model 2 1(reference) 0.99 (0.85,1.15) 1.19 (1.03,1.36) 1.25 (1.08,1.45) 1.67 (1.46,1.92)
Model 3a 1(reference) 0.99 (0.85,1.16) 1.19 (1.04,1.37) 1.25 (1.08,1.45) 1.67 (1.46,1.92)
Model 41 1(reference) 0.99 (0.84,1.17) 1.11 (0.96,1.30) 1.13 (0.96,1.32) 1.40 (1.20,1.63)
Central obesity
Unadjusted 1(reference) 1.11 (0.96,1.27) 1.16 (1.02,1.32) 1.32 (1.15,1.52) 1.60 (1.40,1.82)
Model 1 1(reference) 1.09 (0.95,1.26) 1.15 (1.01,1.31) 1.31 (1.13,1.50) 1.60 (1.40,1.82)
Model 2 1(reference) 1.09 (0.95,1.26) 1.15 (1.01,1.31) 1.29 (1.12,1.49) 1.59 (1.39,1.82)
Model 3b 1(reference) 1.12 (0.97,1.30) 1.18(1.03,1.34) 1.32(1.14,1.52) 1.61 (1.41,1.85)
Model 42 1(reference) 1.12 (0.95,1.31) 1.06(0.91,1.23) 1.15(0.98,1.35) 1.29 (1.11,1.51)
Hypertension
Unadjusted 1(reference) 1.00 (0.87,1.16) 1.26 (1.10,1.45) 1.41 (1.22,1.64) 1.66 (1.44,1.91)
Model 1 1(reference) 1.03 (0.89,1.19) 1.30 (1.13,1.49) 1.46 (1.25,1.69) 1.70 (1.47,1.96)
Model 2 1(reference) 1.03 (0.89,1.20) 1.30 (1.13,1.50) 1.45 (1.24,1.68) 1.70 (1.47,1.96)
Model 3c 1(reference) 1.07 (0.92,1.25) 1.35 (1.18,1.560) 1.52 (1.30,1.77) 1.77 (1.53,2.06)
Model 43 1(reference) 1.07 (0.92,1.24) 1.29 (1.12,1.49) 1.40 (1.20,1.64) 1.56 (1.34,1.83)
CHD
Unadjusted 1(reference) 1.12 (0.97,1.30) 1.15 (1.01,1.32) 1.24 (1.08,1.43) 1.34 (1.17,1.53)
Model 1 1(reference) 1.15 (1.00,1.33) 1.17 (1.03,1.34) 1.27 (1.10,1.46) 1.35 (1.18,1.55)
Model 2 1(reference) 1.14 (0.99,1.32) 1.16 (1.02,1.33) 1.24 (1.07,1.43) 1.33 (1.16,1.52)
Model 3d 1(reference) 1.12 (0.97,1.30) 1.11 (0.97,1.28) 1.17 (1.01,1.35) 1.24 (1.08,1.42)
Model 44 1(reference) 1.12 (0.96,1.30) 1.10 (0.96,1.27) 1.18 (1.02,1.37) 1.26 (1.09,1.45)
HF
Unadjusted 1(reference) 0.88 (0.60,1.31) 1.29 (0.93,1.80) 1.15 (0.80,1.65) 1.70 (1.24,2.34)
Model 1 1(reference) 0.93 (0.63,1.38) 1.34 (0.96,1.86) 1.19 (0.83,1.72) 1.72 (1.25,2.38)
Model 2 1(reference) 0.95 (0.64,1.41) 1.32 (0.94,1.85) 1.16 (0.81,1.68) 1.67 (1.21,2.31)
Model 3d 1(reference) 0.96 (0.65,1.43) 1.33 (0.95,1.86) 1.16 (0.81,1.68) 1.65 (1.19,2.29)
Model 44 1(reference) 0.99 (0.66,1.47) 1.30 (0.93,1.83) 1.17 (0.81,1.70) 1.61 (1.15,2.24)
PAD
Unadjusted 1(reference) 0.69 (0.38 ,1.26) 0.59 (0.34,1.05) 0.93 (0.54,1.59) 0.79 (0.46,1.34)
Model 1 1(reference) 0.72 (0.40,1.31) 0.61 (0.34,1.07) 0.96 (0.56,1.64) 0.79 (0.46,1.34)
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CVD, DM, hypertension, CHD, cerebrovascular disease,
HF, PAD, BMI, TC, LDL-C, and diuretic agent use, this as-
sociation was attenuated but still statistically significant
[OR 1.51, 95 % confidence interval (I) (1.30, 1.74) accord-
ing to NCEP-ATPIII criteria, and OR 1.40 95 % CI
(1.20,1.63) according to IDF criteria in men, OR 2.35 95 %
CI (2.00, 2.75) according to NCEP-ATPIII criteria, and
OR 1.65 95 % CI (1.41, 1.94) according to IDF criteria in
women, respectively]. In addition, even in the normal
range of, the ORs for MetS were higher with elevated
SUA categories only in women. When comparing with the
lowest category, according to NCEP ATP III criteria, SUA
concentration between 270 ~ 310 μmol/L [OR 1.31, 95 %
CI (1.12, 1.54)] and 310 ~ 360 μmol/L [OR 1.62, 95 % CI
(1.38, 1.90)] showed a higher risk of prevalence of MetS.
Furthermore, we explored the association between SUA
level and the components of MetS. When compared with
SUV in the lowest category, the highest category of SUA
level was significantly associated with central obesity
[OR1.29, 95 % CI (1.11, 1.51) in men] and hypertension
[OR1.56, 95 % CI (1.34, 1.83) in men, OR 1.66 95 % CI
(1.39, 1.98) in women, respectively] after multiple adjust-
ments. In addition, the ORs of hypertension across cat-
egories of SUA levels in subjects with normouricemia
were 1, 1.07, 1.29, 1.40 (p value for trend < 0.0001) among
men, and 1, 1.06, 1.27, 1.50 (p value for trend < 0.0001),
respectively.
The relationship between serum uric acid categories and
CVD
The relationship between SUA levels and CVD are also
shown in Table 3 and Table 4. In the present study, ele-
vated SUA levels (the highest category) were suggested
to be significantly associated with HF and CHD even
after multiple adjustments for age, sedentary lifestyle,
current smoking habits, alcohol consumption, Family
history of premature CVD, T2DM, hypertension WC,
TC, TG, HDL-C, LDL-C, diuretic agent use [OR 1.26
95 % CI (1.09,1.45) for CHD, and OR 1.61 95 % CI
(1.15,2.24) for HF in men, OR 1.27 95 % CI (1.07,1.50)
for CHD, and OR 1.91 95 % CI (1.29,2.82) for HF in
women, respectively], when compared to the lowest cat-
egory SUA level. In addition, no association between
SUA level and PAD was found in both men and women
after multiple adjustments.
Discussion
In this study, we investigated the association between
SUA levels, MetS and CVD in outpatients who were
suffering with dyslipidemia and receiving lipid-lowering
therapy from multiple centers in China. Despite several
studies which have reported the relationship between SUA
level and MetS and elevating CVD risk in Chinese popula-
tions from single centers [4, 6, 9], a nationally represen-
tative sample is still limited. Furthermore, all of these
studies investigated the association between SUA levels
and MetS or CVD risk separately, but there was little re-
search on the direct relationship between SUA and CVD
in Chinese populations [19]. We found that there was a
positive association between SUA levels, MetS and CVD
in both men and women.
The association between blood lipid and SUA concen-
tration varies with different participants and sample sizes
[4, 6, 8, 9, 23, 24]. Generally, SUA concentration is posi-
tively correlated with TG, TC, LDL-C, and negatively
correlated with HDL-C. In our study, we also observed
that SUA levels were associated with TG and non-HDL-
C but inversely associated with HDL-C in outpatients
who received a lipid-lowering therapy. Nevertheless,
there was no significant relationship between SUA level
and TC and LDL-C found in these outpatients. To our
knowledge, the underlying biological mechanism be-
tween blood lipids and SUA level is still not elucidated.
In this present cross-sectional study, statins were used
by most of these outpatients, which may be responsible
for the unusual relationship between SUA concentration
and blood lipids.
Table 3 The association between SUA and MetS, hypertension, central obesity, and CVD in men (Continued)
Model 2 1(reference) 0.73 (0.40,1.33) 0.59 (0.33,1.04) 0.92 (0.53,1.58) 0.74 (0.43,1.26)
Model 3 d 1(reference) 0.77 (0.42,1.40) 0.62 (0.35,1.10) 0.97 (0.56,1.67) 0.76 (0.45,1.31)
Model 44 1(reference) 0.75 (0.41,1.37) 0.60 (0.34,1.07) 0.93 (0.54,1.61) 0.70 (0.40,1.22)
Model 1: adjusted for age
Model 2: adjusted for variables included in model 1 and sedentary lifestyle, current smoke, alcohol consumption
a Model 3: adjusted for variables included in model 2 and Family history of premature CVD, CHD, cerebrovascular disease, HF, PAD; b Model 3: adjusted for
variables included in model 2 and Family history of premature CVD, CHD, cerebrovascular disease, HF, PAD, T2DM, hypertension; c Model 3: adjusted for variables
included in model 2 and Family history of premature CVD, CHD, cerebrovascular disease, HF, PAD, T2DM; d Model 3: adjusted for variables included in model 2
and Family history of premature CVD, T2DM, hypertension
1 Model 4: adjusted for variables included in model 3a and BMI, TC, LDL-C, Diuretic agents use; 2 Model 4: adjusted for variables included in model 3b and BMI, TC,
TG, HDL-C, LDL-C, Diuretic agents use; 3 Model 4: adjusted for variables included in model 3C and BMI, TC, TG, HDL-C, LDL-C, Diuretic agents use; 4 Model 4:
adjusted for variables included in model 3C and WC, TC, TG, HDL-C, LDL-C, Diuretic agents use
Abbreviations: SUA serum uric acid, MetS metabolic syndrome, CVD cardiovascular disease, ATP National Cholesterol Education Program Adult Treatment Panel III,
IDF International Diabetes Federation, CHD coronary artery disease, TG triglyceride, TC total cholesterol, HDL-C high density lipoprotein cholesterol, LDL-C low
density lipoprotein cholesterol, T2DM type 2 diabetes mellitus, HF heart failure, PAD peripheral artery disease
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Table 4 The association between SUA and MetS, hypertension, central obesity, and CVD in women
SUA levels (μmol/L)
<230 230 ~ 270 270 ~ 310 310 ~ 360 >360
Q1 Q2 Q3 Q4 Q5
MetS ATP
Unadjusted 1(reference) 1.13 (0.97,1.33) 1.43 (1.23,1.66) 1.81 (1.55,2.11) 2.77 (2.39,3.21)
Model 1 1(reference) 1.13 (0.97,1.33) 1.43 (1.23,1.66) 1.81 (1.55,2.11) 2.77 (2.39,3.22)
Model 2 1(reference) 1.13 (0.97,1.32) 1.42 (1.22,1.65) 1.79 (1.54,2.09) 2.76 (2.38,3.21)
Model 3a 1(reference) 1.12 (0.96,1.32) 1.41 (1.21,1.64) 1.78 (1.53,2.08) 2.71 (2.34,3.16)
Model 41 1(reference) 1.08 (0.92,1.28) 1.31 (1.12,1.54) 1.62 (1.38,1.90) 2.35 (2.00,2.75)
MetS IDF
Unadjusted 1(reference) 1.01 (0.87,1.17) 1.22 (1.06,1.42) 1.41 (1.21,1.63) 2.05 (1.77,2.37)
Model 1 1(reference) 1.01 (0.87,1.18) 1.23 (1.06,1.42) 1.42 (1.22,1.65) 2.09 (1.80,2.42)
Model 2 1(reference) 1.00 (0.86,1.17) 1.22 (1.05,1.42) 1.40 (1.21,1.63) 2.08 (1.80,2.42)
Model 3a 1(reference) 1.00 (0.86,1.17) 1.21 (1.05,1.41) 1.40 (1.20,1.62) 2.06 (1.77,2.39)
Model 41 1(reference) 0.94 (0.80,1.10) 1.08 (0.92,1.26) 1.20 (1.02,1.41) 1.65 (1.41,1.94)
Central obesity
Unadjusted 1(reference) 1.06 (0.90,1.25) 1.19 (1.01,1.39) 1.26 (1.07,1.48) 1.50 (1.28,1.76)
Model 1 1(reference) 1.06 (0.91,1.25) 1.19 (1.02,1.40) 1.28 (1.08,1.50) 1.56 (1.33,1.83)
Model 2 1(reference) 1.06 (0.90,1.25) 1.19 (1.01,1.40) 1.27 (1.08,1.49) 1.56 (1.33,1.83)
Model 3b 1(reference) 1.06 (0.90,1.25) 1.18 (1.00,1.38) 1.24 (1.05,1.46) 1.49 (1.27,1.76)
Model 42 1(reference) 0.95 (0.80,1.14) 0.95 (0.80,1.14) 0.97 (0.80,1.16) 1.04 (0.86,1.25)
Hypertension
Unadjusted 1(reference) 1.11 (0.95,1.30) 1.38 (1.18,1.61) 1.75 (1.49,2.05) 2.37 (2.02,2.78)
Model 1 1(reference) 1.11 (0.95,1.30) 1.36 (1.16,1.59) 1.68 (1.43,1.98) 2.07 (1.76,2.44)
Model 2 1(reference) 1.10 (0.94,1.29) 1.35 (1.15,1.58) 1.67 (1.42,1.96) 2.06 (1.75,2.43)
Model 3c 1(reference) 1.10 (0.94,1.30) 1.36 (1.15,1.60) 1.65 (1.40,1.95) 1.97 (1.67,2.33)
Model 43 1(reference) 1.06 (0.89,1.25) 1.27 (1.08,1.50) 1.50 (1.26,1.79) 1.66 (1.39,1.98)
CHD
Unadjusted 1(reference) 1.12 (0.95,1.32) 1.22 (1.04,1.44) 1.38 (1.18,1.63) 1.68 (1.44,1.96)
Model 1 1(reference) 1.12 (0.95,1.33) 1.21 (1.02,1.43) 1.32 (1.02,1.43) 1.44 (1.23,1.67)
Model 2 1(reference) 1.12 (0.94,1.33) 1.20 (1.02,1.42) 1.31 (1.11,1.54) 1.42 (1.23,1.67)
Model 3d 1(reference) 1.10 (0.93,1.31) 1.15 (0.97,1.36) 1.22 (1.03,1.45) 1.30 (1.11,1.53)
Model 44 1(reference) 1.10 (0.92,1.31) 1.14 (0.96,1.36) 1.20 (1.01,1.42) 1.27 (1.07,1.50)
HF
Unadjusted 1(reference) 1.31 (0.85,2.04) 1.34 (0.87,2.06) 1.64 (1.08,2.47) 2.89 (1.99,4.21)
Model 1 1(reference) 1.33 (0.86,2.07) 1.33 (0.86,2.04) 1.54 (1.01,2.34) 2.31 (1.58,3.38)
Model 2 1(reference) 1.33 (0.85,2.07) 1.32 (0.85,2.04) 1.48 (0.97,2.26) 2.27 (1.55,3.33)
Model 3d 1(reference) 1.35 (0.87,2.11) 1.28 (0.83,1.98) 1.40 (0.92,2.14) 2.13 (1.45,3.12)
Model 44 1(reference) 1.32 (0.85,2.07) 1.22 (0.79,1.90) 1.31 (0.85,2.01) 1.91 (1.29,2.82)
PAD
Unadjusted 1(reference) 1.15 (0.44,3.00) 2.26 (0.99,5.19) 1.84 (0.78,4.36) 2.72 (1.23,6.02)
Model 1 1(reference) 1.15 (0.44,3.00) 2.24 (0.98,5.13) 1.77 (0.75,4.20) 2.42 (1.09,5.39)
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An inverse relationship between SUA concentration
and FPG was found in the present study and SUA in the
lowest category was found to have an extremely high
FPG. This negative association of SUA and diabetic pa-
rameters was reported in a previous study in Chinese
T2DM [4]. Another study in Taiwan also found a nega-
tive association between SUA level and hyperglycemia in
men, but not in women [23]. Moreover, several studies
performed in western populations showed a bell-shaped
association between SUA concentration and plasma glu-
cose [25, 26]. Among normal fasting glucose and normal
glucose tolerance, a positive association was found be-
tween SUA level and FPG and 2-h postprandial glucose
(2 h-PPG) [24]. In our study, we found that subjects in
the lowest SUA category had a higher prevalence of DM,
which is consistent with a previous study [11]. Parti-
cularly, in diabetics, hyperglycemia can increase renal
excretion of uric acid, leading to decreasing SUA con-
centration. Furthermore, ethnic differences may also be
one reason for the inconsistency between studies. How-
ever, we suggest that more prospective cohort studies
with different populations should be performed to eva-
luate the association between SUA concentration and
plasma glucose.
Several cross-sectional studies have observed an inde-
pendent effect of elevating SUA level on MetS [4, 23, 27].
This independent effect is maintained among teenagers
and the elderly [8, 9]. Furthermore, longitudinal studies
also demonstrated that SUA is an independent predictor
for MetS incidence [27, 28]. Similar to those studies, our
results showed that elevated SUA level had an independ-
ently increased risk of MetS and this was statistically sig-
nificant between the lowest and highest categories of SUA.
Meanwhile, SUA concentration was accompanied with an
increasing number of MetS components [4]. This relation-
ship has been shown in both men and women, while the
prevalence of MetS was higher among women than
among men [3]. A study from Taiwan suggested that the
association between SUA level and MetS was more robust
in women than in men, in which hyperuricemia was at-
tributed to be a significantly independent predictor for
MetS in women, but not in men [29]. Data from another
observational study performed in the mainland of China
also corresponded to this phenomenon [30]. Similarly, our
present study indicated that the positive association
remained both genders. Moreover, women seemed to ex-
hibit a stronger association than men.
Several longitudinal studies have indicated that SUA is
an independent risk factor of CVD, CVD related mortality
and all-cause mortality [10, 11, 31]. However, two well-
known cohort studies suggested that SUA levels were not
associated with these outcomes [13, 14]. Moreover, several
Mendelian randomization Studies, which were performed
in westernized populations, suggested that high uric acid
or hyperuricemia was causally related to adverse CVD [32,
33]. Controversy about the relationship between SUA
levels and CVD has lasted several decades. For Chinese
populations, SUA concentration was related with CVD
events from two Taiwan cohort studies [19, 34]. Data for
this relationship from the mainland of China is still lim-
ited. In our present study, we tried to calculate the associ-
ation between SUA level and CVD in Chinese outpatients
treated with lipid-lowering agents. A mild positive associ-
ation between SUA level and HF and CHD was found in
both men and women after adjusting for multi-variables.
We suggest that the association between SUA level and
CHD and HF may be independent of MetS and other con-
founders accounted in our present study. However, the
causal effect between SUA levels and CHD is still not
clear. Moreover, experimental data showed that uric acid
may have both anti- and pro-oxidant effects. These two
contradictory biochemical reactions may be dependent on
the cellular environment [35]. So we suggest more experi-
ments should be performed to make clear the biological
mechanism underling the relationship between SUA levels
and CVD.
Table 4 The association between SUA and MetS, hypertension, central obesity, and CVD in women (Continued)
Model 2 1(reference) 1.15 (0.44,3.00) 2.20 (0.96,5.05) 1.68 (0.71,3.99) 2.35 (1.05,5.24)
Model 3d 1(reference) 1.20 (0.46,3.13) 2.16 (0.94,4.97) 1.55 (0.65,3.70) 2.09 (0.93,4.68)
Model 44 1(reference) 1.16 (0.44,3.04) 2.10 (0.91,4.87) 1.59 (0.66,3.82) 2.07 (0.91,4.71)
Model 1: adjusted for age
Model 2: adjusted for variables included in model 1 and sedentary lifestyle, current smoke, alcohol consumption
aModel 3: adjusted for variables included in model 2 and Family history of premature CVD, CHD, cerebrovascular disease, HF, PAD; b Model 3: adjusted for
variables included in model 2 and Family history of premature CVD, CHD, cerebrovascular disease, HF, PAD, T2DM, hypertension; c Model 3: adjusted for variables
included in model 2 and Family history of premature CVD, CHD, cerebrovascular disease, HF, PAD, T2DM; d Model 3: adjusted for variables included in model 2
and Family history of premature CVD, T2DM, hypertension
1 Model 4: adjusted for variables included in model 3a and BMI, TC, LDL-C, Diuretic agents use; 2 Model 4: adjusted for variables included in model 3b and BMI, TC,
TG, HDL-C, LDL-C, Diuretic agents use; 3 Model 4: adjusted for variables included in model 3C and BMI, TC, TG, HDL-C, LDL-C, Diuretic agents use; 4 Model 4:
adjusted for variables included in model 3C and WC, TC, TG, HDL-C, LDL-C, Diuretic agents use
Abbreviations: SUA serum uric acid, MetS metabolic syndrome, CVD cardiovascular disease, ATP National Cholesterol Education Program Adult Treatment Panel III,
IDF International Diabetes Federation, CHD coronary artery disease, TG triglyceride, TC total cholesterol, HDL-C high density lipoprotein cholesterol, LDL-C low
density lipoprotein cholesterol, T2DM type 2 diabetes mellitus, HF heart failure, PAD peripheral artery disease
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Limitations
As a cross-sectional study, the present study has some
limitations. First, all of the participants enrolled in our
study are outpatients who were suffering from dyslipid-
emia and receiving a lipid-lowering therapy for at least
3 months. Second, although the biochemical markers
and CVD events were carefully documented by investi-
gators, there still might be some accidental errors.
Confounders, such as plasma insulin, CRP and dietary
fructose were not available. Third, the definition of CVD
events in our present study varies from previous studies
[14, 19]. However, the sample in our present study is
large, and all of the participants were from multiple cen-
ters in the mainland of China, and the investigators are
all clinicians. Furthermore, confounders, such as physical
activity, alcohol consumption, the use of diuretics were
included in our study. However, further population-
based prospective cohort studies should been performed
in Chinese populations to confirm the association be-
tween SUA, MetS and CVD.
Conclusions
In summary, serum uric acid was significantly associated
with metabolic syndrome, HF and CHD in Chinese out-
patients treated with lipid-lowering agents after adjust-
ment for multiple confounders. Moreover, there seems
to be an inverse relationship between fasting plasma glu-
cose and serum uric acid. Thus, both experiments in
vitro and human trials should be conducted to investi-
gate the biochemical mechanism by which elevated
serum uric acid gives rise to metabolic syndrome and
CVD.
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